头颈部癌症根治性或辅助性放疗后头颈部淋巴水肿的临床、病理及剂量学预测因素
该单中心回顾性研究纳入76例接受根治性或辅助性放疗±化疗的头颈部癌症患者,中位随访550天,360天时外部和内部头颈部淋巴水肿发生率分别为70%和34%。多变量竞争风险模型显示,诊断时晚期淋巴结状态预测外部和内部淋巴水肿风险增加;淋巴结清扫数目增加预测外部淋巴水肿风险;对侧VII区淋巴结V30≥50%预测外部淋巴水肿,喉V45≥50%是内部淋巴水肿最重要的剂量学预测因素。
要点
- 360天时外部和内部头颈部淋巴水肿发生率分别为70%和34%。
- 诊断时晚期淋巴结状态预测外部和内部淋巴水肿风险增加。
- 对侧VII区淋巴结V30≥50%和喉V45≥50%分别为外部和内部淋巴水肿的剂量学预测因素。
核心结论
- 头颈部癌症治疗后头颈部淋巴水肿常见,诊断时淋巴结病变负荷预测外部和内部淋巴水肿风险增加。
研究设计与样本
- 单中心回顾性收集76例连续接受根治性或辅助性放疗±化疗的头颈部癌症患者的临床、病理和剂量学数据,使用竞争风险回归构建并优化多变量模型。
主要发现
- 中位随访550天,360天时外部和内部头颈部淋巴水肿发生率分别为70%和34%。
- 仅用临床和治疗因素时,淋巴结清扫数目和晚期淋巴结状态预测外部淋巴水肿。
- 纳入剂量学变量后,外部淋巴水肿优化模型包括对侧VII区淋巴结V30≥50%、淋巴结清扫数目和晚期淋巴结状态。
- 内部淋巴水肿的临床病理模型识别辅助放疗(相对于根治性放疗)和晚期淋巴结状态。
- 纳入剂量学变量后,内部淋巴水肿优化模型包括喉V45≥50%和晚期淋巴结状态。
关键数值与推荐
- 外部淋巴水肿优化模型纳入对侧VII区淋巴结V30≥50%、淋巴结清扫数目和晚期淋巴结状态。
- 内部淋巴水肿优化模型纳入喉V45≥50%和晚期淋巴结状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Head and neck lymphedema (HNL) following radiation therapy for head and neck cancer (HNC) causes patient morbidity. Predicting individual patients' risk of HNL after treatment is challenging. We aimed to identify the demographic, disease-related, and treatment-related factors associated with external and internal HNL following treatment of HNC with definitive or adjuvant radiation therapy. METHODS AND MATERIALS: Relevant clinical, pathologic, and dosimetric data for 76 consecutive patients who received definitive or adjuvant radiation ± chemotherapy were retrospectively collected from a single institution. Multivariable models predictive of external and internal lymphedema using clinicopathologic variables alone and in combination with dosimetric variables were constructed and optimized using competing risk regression. RESULTS: After median follow-up of 550 days, the incidence of external and internal HNL at 360 days was 70% and 34%, respectively. When evaluating clinical and treatment-related factors alone, number of lymph nodes removed and advanced adenopathy status were predictive of external lymphedema. With incorporation of dosimetric variables, the optimized model included the percentage volume of the contralateral lymph node level VII receiving 30Gy V30 ≥50%, number of lymph nodes removed, and advanced adenopathy status. For internal lymphedema, our clinicopathologic model identified both adjuvant radiation, as opposed to definitive radiation, and advanced adenopathy status. With inclusion of a dosimetric variable, the optimized model included larynx V45 ≥50% and advanced adenopathy. CONCLUSIONS: HNL following HNC treatment is common. For both external and internal lymphedema, nodal disease burden at diagnosis predicts increased risk. For external lymphedema, increasing extent of lymph node dissection prior to adjuvant therapy increases risk. The contralateral level VII lymph node region is also predictive of external lymphedema when radiation dose to V30 is ≥50%, meriting investigation. For internal lymphedema, we confirm that increasing radiation dose to the larynx is the most significant dosimetric predictor of mucosal edema when larynx V45 is ≥50%.
引用
- Rogacki KR, Teo PT, Gopalakrishnan M, et al. Clinical, Pathologic, and Dosimetric Predictors of Head and Neck Lymphedema Following Definitive or Adjuvant Radiation Therapy for Head and Neck Cancer. Adv Radiat Oncol. 2024. PMID: 39184143. doi:10.1016/j.adro.2024.101545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。